To: IFCC Full and Affiliate Members’ Representatives Corporate Members’ Representatives

Dear All,

As of January 2019 the IFCC has recently created a Committee on “Bone Metabolism (C-BM)”, formed by the joining of the already existing Working Groups:

    • Standardization of Bone Markers Assays (WG-BMA) in collaboration with IOF
    • Parathyroid Hormone (WG-PTH)
    • Vitamin D Standardization Program (WG-Vit D)

The Committee on Bone Metabolism will be chaired by Prof. Etienne Cavalier, Head of the Department of Clinical Chemistry at the University of Liège (etienne.cavalier@chu.ulg.ac.be) and current Chair of the WG-BMA.
The Membership will be composed by the Chair and 4 Members, out of these one position will be reserved for a young scientists (less than 40 years).

The Terms of Reference of the new functional units are following ones:

  • Standardize PTH assays
  • Standardize or harmonize bone markers assays
  • Standardize vitamin D metabolites assays

 

As current Projects the Committee will focus on:

1.PTH assays

  • Create liaison with International Endocrinological, Rheumatological and Nephological organizations
  • Define the measurand (what we need to measure for all clinical situations)
  • Develop a reference measurement procedure for PTH(1-84) and moieties of clinical interest
  • Evaluate the commutability of PTH International standard PTH 95/646 and the need to create primary reference material
  • Replicate the RMP in a second lab and create a network of 3-4 reference labs
  • Create an accuracy-based external quality assessment scheme
  • Constitute an appropriate and international panel of sera and plasma to establish PTH reference intervals
  • Specify performance criteria for RMP and routine methods
  • Provide services to manufacturers, notably by providing a reliable source for primary reference materials
  • Post-survey of the standardization effects

 

2. Bone markers assays

  • Continue the liaison with IOF and extend to other relevant international societies
    Current CTX and PINP project:
  • complete the multicenter study and harmonize CTX and PINP assays
  • Collaborate with EQAS provider(s) to improve the surveys
  • Constitute an appropriate and international panel of sera and plasma to establish CTX and PINP reference intervals
  • Post-survey of the standardization/harmonization effects.
  • Future projects:
  • Select biomarkers to be standardized/harmonized (e.g.: bone alkaline phosphatase, FGF-23, sclerostin).

3. Vitamin D metabolites

  • Re-evaluate current VDSP performance guidelines for 25(OH)D
  • Establish VDSP performance guidelines for 24,25(OH)2D, C3-epimer and vitamin D binding protein
  • Post-survey of the standardization effects
  • Propose services to reassess the true value of 25OHD obtained in former epidemiological or interventional studies that had used non-standardized methods

Leave a Comment

Your email address will not be published. Required fields are marked *